Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Earlier in our article, we discussed how mostly off-label therapies so far dominate the NASH therapeutics market. So, let us dig deeper into it and find out what can we expect in the coming years ...
NASH market share of off label therapies, it will keep on experiencing a steady growth until a standard approved therapy enters the NASH treatment market. Non-alcoholic fatty liver disease (...
NASH is defined as the most common form of Nonalcoholic fatty liver disease (NAFLD). The disease is characterized by a spectrum of symptoms including simple steatosis, increased levels of fibrosis...
With the advent of new-age healthcare industry trends that are evident as of now, there...
Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...
The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...
Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...
There has been limited progress in the approval of novel agents in MDS. It has been a l...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
